BioCentury
ARTICLE | Clinical News

ARG201 regulatory update

February 18, 2008 8:00 AM UTC

FDA granted Orphan Drug designation for ARG201 to treat diffuse systemic sclerosis. arGentis has completed a Phase II trial of the solubilized type I native bovine collagen for the indication. ...